🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#MEDIA: Announcing that the #CHMP adopted a positive opinion for our subcutaneous #immunotherapy treatment option for certain patients with cancer. bit.ly/3FLDmcf

#MEDIA: The EMA #CHMP issued a positive opinion for our #immunotherapy-based regimen as a perioperative treatment for certain patients with resectable non-small cell #lungcancer. bit.ly/4j7HGRw

MEDIA: U.S. FDA approves a first-line immunotherapy treatment option for certain patients with a type of colorectal cancer. bit.ly/4i4xgB5

MEDIA: U.S. FDA approves first-line dual immunotherapy treatment option for certain patients with hepatocellular carcinoma. bit.ly/3Ed4Yqp

#MEDIA: The U.S. FDA approved an update to the required echo monitoring for our first-in-class treatment for adults living with symptomatic obstructive #HypertrophicCardiomyopathy: bit.ly/3YCuKuZ

#MEDIA: The European Commission has approved our #immunotherapy-based combination treatment as a perioperative regimen for certain patients with resectable non-small cell #lungcancer. bit.ly/43bswWt

We are excited to debut data across our oncology portfolio and pipeline at this year’s #ASCO25. Our presentations include the latest cutting-edge research across immunotherapy, cell therapy, targeted protein degradation, and more. bit.ly/43HRk8y

#MEDIA: The European Commission has approved our subcutaneous #immunotherapy treatment regimen for eligible patients with certain cancers. bit.ly/4jkbQk7

As we kick off #ASCO25, we’re reminded that cancer care is about more than medicine. In 2019, we set out to create a space dedicated to uniting #cancer survivors called SurvivorshipToday.com. Years later, we're proud of the community we've built: bit.ly/43fsj4q

Our diverse pipeline and portfolio are driven by a deep understanding of causal human biology and the complexities of cancer. We look forward to presenting data at this year’s #ASCO25, #EHA2025 and #18ICML. Learn more: bit.ly/43vXVle

In collaboration with SystImmune, we’re continuing to push the boundaries in #lungcancer research with dual-targeted antibody-drug conjugates (ADCs). Our data at #ASCO25 showcase our efforts to bringing new hope to patients. bit.ly/44X9aFL #LCSM

Today, we announced a global strategic partnership with BioNTech SE to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody, across numerous solid tumor types. Learn more: bit.ly/4kMbwMj

#MEDIA: Today at #EULAR2025, we announced new late-breaking data from a pivotal Phase 3 trial for an investigational medicine in adult patients with active #PsoriaticArthritis. Read more: bit.ly/4jGd2yt

#MEDIA: Announcing updated results evaluating the safety and efficacy in our potential first-in-class oral CELMoD agents for the treatment of patients with blood cancers. bit.ly/3SPGkjh

#MEDIA: Today we announced new data for our #CARTcelltherapy in different types of relapsed or refractory blood cancers at #18ICML. bit.ly/45UwFzx

#MEDIA: U.S. FDA has approved the removal of REMS and streamlined patient monitoring requirements for our #CARTcelltherapies, a landmark update that will help foster increased patient access for this important treatment modality. bit.ly/4nm69FJ

#MEDIA Announcing our first-of-its-kind RayzeBio site in Indianapolis, a cutting-edge U.S. manufacturing facility advancing our mission to deliver innovative medicines to patients.

#MEDIA: Today, we announced a major milestone regarding applications for our investigational medicine for the treatment of adults with active psoriatic arthritis that were submitted in the U.S., China, Japan and European Union. Read more: bit.ly/45dOgBJ

#MEDIA: Today, we announced Cristian Massacesi, MD, as EVP, Chief Medical Officer and Head of Drug Development. He brings extensive experience to our leadership team as we continue driving innovation and delivering transformative medicines to patients. bit.ly/4kVBHzC

#MEDIA: We received an FDA acceptance of the regulatory filing with priority review for our personalized treatment option for adult patients with relapsed or refractory marginal zone lymphoma #MZL bit.ly/450msko